BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-9803 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-9803\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06906731-11118@assetmemo.bio
DTSTAMP:20261121T005555Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-9803: Phase 1/2 readout est. (NCT06906731)
DESCRIPTION:SHR-9803\, phase 1/2\, Advanced Solid Tumors.\nStudy: A Study o
 f SHR-9803 for Injection in Patients With Advanced Solid Tumors\nEstimated
  primary completion: June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/shr-9803#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT06906731
URL:https://assetmemo.bio/drug/shr-9803#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
